Eli Lilly Reports Results of Solanezumab in P-II/III DIAN-TU Study for Dominantly Inherited Alzheimer’s Disease

 Eli Lilly Reports Results of Solanezumab in P-II/III DIAN-TU Study for Dominantly Inherited Alzheimer’s Disease

Eli Lilly Reports Results of Solanezumab in P-II/III DIAN-TU Study for Dominantly Inherited Alzheimer’s Disease

Shots:

  • The P-II/III DIAN-TU study involves assessing of solanezumab (400mg/q4w as initial dose and increased to ~25% of the total doses being administered @1600mg) vs PBO in patients with at risk for or with dominantly inherited Alzheimer’s disease, caused by rare gene mutations  
  • The P-II/III DIAN-TU study resulted in not meeting its 1EPs with its analysis for 2EPs are ongoing by Washington University and Lilly. The negative results do not impact ongoing A4 study of solanezumab
  • Solanezumab is an investigational anti-amyloid mAb, currently being evaluated in preclinical Alzheimer’s disease in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post